BIOLOGICAL · Unmapped registry intervention
Albumin 5%
Find medicine records ·
Find other trials using this name
Clinical trial
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
NCT01561053
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
Albumin 20%
Find medicine records ·
Find other trials using this name
BIOLOGICAL · Unmapped registry intervention
Immunoglobulin
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2, PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Alzheimer's Diseaseverified · MONDO: Alzheimer disease
Interventions
Sponsors & collaborators
Instituto Grifols, S.A.lead sponsor
Grifols Biologicals, LLCcollaborator
Mapped research locations
MiamiFlorida, United States3BarcelonaSpain3MadridSpain2ValenciaSpain2ClevelandOhio, United States1PittsburghPennsylvania, United States1Washington D.C.District of Columbia, United States1DenverColorado, United States1CharlestonSouth Carolina, United States1SacramentoCalifornia, United States1DaytonOhio, United States1DecaturGeorgia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01561053 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.